Overview

• Unitaid, CHAI and Wits RHI signed an agreement with Dr Reddy's to supply generic lenacapavir to 120 low‑ and middle‑income countries starting in 2027.
• The Gates Foundation announced a separate manufacturing partnership with Hetero to produce generics for distribution in eligible countries.
• The agreed price is $40 per patient‑year, with initial production based in India and plans to regionalize manufacturing over time.
• These arrangements build on Gilead's October 2024 voluntary licences to six generic makers and on recent U.S. and EU regulatory clearances.
• Lenacapavir is a twice‑yearly injectable PrEP; the branded U.S. product costs about $28,000 per year, while an interim Global Fund–Gilead pathway aims first shipments to at least one African country by late 2025.